~~<i id='EA85687E77'><strike id='EA85687E77'><tt id='EA85687E77'><pre id='EA85687E77'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：focus 2025-09-06 03:55:39 - browse：9975

An FDA sign — health policy coverage from STAT — Sarah Silbiger/Getty Images

WASHINGTON — There’s about to be a new acronym in town.

The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

That overhaul includes a new name: Meet the Office of Inspections and Investigations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Researchers on aging grapple with how to calculate biological age

explore

knowledge

explore

hotspot

leisure time

explore

Afterphysicallydebilitatingcancertreatment,LaurieBrunnerencounteredanothermedicalhurdle:Shehaddevelo

WSS

After gene therapy, two congenitally deaf children hear for the first time

H5N1 bird flu: what we're starting to learn about infection in cows

Nick Jonas talks about managing diabetes along with his career

European regulators consider appeal over Amylyx ALS drug

Dairy farmers resist CDC push for PPE against bird flu virus

There’s no way to know how good AI health technologies are

hotspot

entertainment

explore

Medicare details structure of new drug price negotiation program

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Guidelines to prevent youth baseball injuries need more muscle

Software glitch causes Tandem insulin pump to shutdown, FDA warns

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sanofi strikes deal with Novavax, boosting the vaccine maker

Anesthesiologist group: stop taking Ozempic before surgery

Takeaways from AdvaMed, the largest medical devices conference

How to save PrEP access — and even expand it

Life sciences deals on track to hit lowest point since 2017

knowledge

There’s no way to know how good AI health technologies are

Sanofi strikes deal with Novavax, boosting the vaccine maker

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Life sciences deals on track to hit lowest point since 2017

Wellcome Trust names Røttingen as its new CEO

Telehealth startups turn to complex chronic diseases

explore

hotspot

leisure time

explore